Skip to main content
Fig. 3 | Cancer & Metabolism

Fig. 3

From: Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia

Fig. 3

Prolonged hepatic ChREBP normalization in L-G6pc−/− mice promotes Yes Associated Protein (YAP) transcriptional activity. Data after 21–26 days of shChREBP/L-G6pc−/− and n = 8, unless stated otherwise. (A) Mitotic figures and BrdU positivity (n = 4–6, 20–21 days). (B) YAP-target genes and Shp. (C) YAP nuclear protein and whole liver lysate pYAP/YAP ratio (Blots/Ponceau S: Fig. S2C-E). (D) Correlations between liver weight and Ctgf expression in shChREBP/L-G6pc−/− mice. (E) Expression of bile acid synthesis enzymes and transporters, and (F) Total plasma bile acid levels. A/C/F-G: median ± interquartile range. E: box-and-whisker plots. A/C/F-G: Kruskal Wallis H-test, post-hoc Conover pairwise comparisons, *p < 0.05, **p < 0.01, ***p < 0.001 vs shSCR/L-G6pc+/+; ^ vs shChREBP/L-G6pc+/+; # vs shSCR/L-G6pc−/−

Back to article page